angioedema secondary to c1 inhibitor deficiency has been rarely reported to be associated with systemic lupus erythematosus. a genetic defect of c1 inhibitor produces hereditary angioedema, which is usually presented with cutaneous painless edema, but edema of the genital area, gastrointestinal and laryngeal tracts have also been reported. in lupus patients, angioedema may be the result of an a...

ANA: antinuclear antibody BID: twice a day CLE: cutaneous lupus erythematosus DIL: drug-induced lupus SLE: systemic lupus erythematosus INTRODUCTION Cutaneous lupus erythematosus (CLE), defined as isolated cutaneous lesions without significant systemic involvement, has a reported incidence and prevalence of 4.3 and 73.2 per 100,000, respectively. It occurs more commonly among women with a repor...

Background: Systemic lupus erythematous (SLE) is a multisystemic and autoimmune inflammatory disease characterized by production of autoantibodies against different cellular components. We aimed to investigate children with SLE in terms of clinical symptoms and laboratory findings who referred to Lupus clinic.Materials and Methods: In this cross-sectional study, 36 children with SLE refer...

tures and functional outcomes. Lupus 1996; 5: 294-9. 8. MOK CC, LAU CS, CHAN YET, WONG RWS: Acute transverse myelopathy in systemic lupus erythematosus: Clinical presentation, treatment and outcome. J Rheumatol 1998; 25: 467-73. 9. OSAWA H, YAMABE H, KAIZUKA M, et al.: Systemic lupus erythematosus associated with transverse myelitis and parkinsonism symptoms. Lupus 1997; 6: 613-5. 10. BAVILE L,...

Podocytopathy in systemic lupus erythematosus is characterised by diffuse foot process effacement without significant peripheral capillary wall immune deposits as seen on electron microscopy. Lupus podocytopathy falls outside the scope of the current International Society of Nephrology and the Renal Pathology Society classification of lupus nephritis. We present a case of relapsing podocytopath...

Accepted 23 October 2012 ABSTRACT Objectives To evaluate treatment with the peptidebased agent, Lupuzor, in a double-blind, randomised, placebo-controlled study of patients with systemic lupus erythematosus. Methods Patients who met ≥4 of the American College of Rheumatology criteria, had a score of ≥6 on the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and did not have ...

Bullous systemic lupus erythematosus has rarely been described in pediatric lupus population and the real prevalence of childhood-onset bullous systemic lupus erythematosus has not been reported. From January 1983 to November 2013, 303 childhood-onset SLE (c-SLE) patients were followed at the Pediatric Rheumatology Unit of the Childreńs Institute of Hospital das Clínicas da Faculdade de Medicin...

paraoxonase-1 (pon1) is a serum hdl-bound enzyme that hydrolyzes a number of aromatic carboxylic acid esters including lipid peroxides, preventing ldl oxidation. systemic lupus erythematosus (sle) patients are at greater risk of oxidative stress, which is associated with abnormal plasma lipid metabolism. in this study, association of pon-55 polymorphism with serum arylesterase (are) activities,...

0